Date | Time | Source | Headline | Symbol | Company |
06/10/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT | NASDAQ:ALT | Altimmune Inc |
06/05/2024 | 7:00AM | GlobeNewswire Inc. | Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | NASDAQ:ALT | Altimmune Inc |
06/05/2024 | 5:45AM | PR Newswire (US) | Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT | NASDAQ:ALT | Altimmune Inc |
05/29/2024 | 7:31AM | GlobeNewswire Inc. | Altimmune to Participate at Two Upcoming Investor Conferences | NASDAQ:ALT | Altimmune Inc |
05/29/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 | NASDAQ:ALT | Altimmune Inc |
05/29/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline | NASDAQ:ALT | Altimmune Inc |
05/21/2024 | 9:00AM | PR Newswire (US) | Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) | NASDAQ:ALT | Altimmune Inc |
05/21/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT | NASDAQ:ALT | Altimmune Inc |
05/14/2024 | 5:45AM | PR Newswire (US) | Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) | NASDAQ:ALT | Altimmune Inc |
05/10/2024 | 5:45AM | PR Newswire (US) | The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders | NASDAQ:ALT | Altimmune Inc |
05/09/2024 | 5:51PM | PR Newswire (US) | INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm | NASDAQ:ALT | Altimmune Inc |
05/09/2024 | 4:05PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ALT | Altimmune Inc |
05/09/2024 | 7:04AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ALT | Altimmune Inc |
05/09/2024 | 7:00AM | GlobeNewswire Inc. | Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:ALT | Altimmune Inc |
05/07/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Participate at Two Upcoming Investor Conferences | NASDAQ:ALT | Altimmune Inc |
05/02/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 | NASDAQ:ALT | Altimmune Inc |
05/01/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Participate at Two Upcoming Conferences | NASDAQ:ALT | Altimmune Inc |
04/25/2024 | 5:24PM | GlobeNewswire Inc. | Altimmune Statement on the Passing of Dr. Stephen Harrison | NASDAQ:ALT | Altimmune Inc |
03/27/2024 | 7:00AM | GlobeNewswire Inc. | Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ALT | Altimmune Inc |
03/27/2024 | 6:57AM | IH Market News | U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading | NASDAQ:ALT | Altimmune Inc |
03/20/2024 | 7:30AM | GlobeNewswire Inc. | Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 | NASDAQ:ALT | Altimmune Inc |
02/14/2024 | 12:04PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ALT | Altimmune Inc |
02/14/2024 | 6:37AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ALT | Altimmune Inc |
02/05/2024 | 6:02PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/05/2024 | 6:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/05/2024 | 6:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/01/2024 | 6:03PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/01/2024 | 6:02PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/01/2024 | 6:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |
02/01/2024 | 6:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ALT | Altimmune Inc |